Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary A Katofiasc

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Life Sciences|July 11, 2002
Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in catsMary A Katofiasc, Jeffrey Nissen, James E Audia, et al.
Journal of Neurotrauma|October 24, 2019
Chronic, Twice-Daily Dosing of an NK2 Receptor Agonist [Lys<sup>5</sup>,MeLeu<sup>9</sup>,Nle<sup>10</sup>]-NKA(4-10), Produces Consistent Drug-Induced Micturition and Defecation in Chronic Spinal RatsLesley Marson, Raymond Keast Piatt, Mary A Katofiasc, et al.
Brain Research|July 26, 2002
The role of 5-HT(1A) receptors in control of lower urinary tract function in catsKarl B Thor, Mary A Katofiasc, Hansjorg Danuser, et al.
Canadian Journal of Physiology and Pharmacology|January 30, 2023
Colorectal and bladder prokinetic activity of [Lys<sup>5</sup>, MeLeu<sup>9</sup>, Nle<sup>10</sup>]-NKA<sub>(4-10)</sub> after intranasal or sublingual delivery in dogsNadia M J Rupniak, Mary A Katofiasc, Jungeun Bae, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 19, 2024
Recent Developments in On-Demand Voiding TherapiesKarl B Thor, Lesley Marson, Mary A Katofiasc, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 20, 2025
Corrigendum to "Recent Developments in On-Demand Voiding Therapies" [The Journal of Pharmacology and Experimental Therapeutics 390 (2024) 302-317]Karl B Thor, Lesley Marson, Mary A Katofiasc, et al.
Neuropeptides|July 21, 2019
Prokinetic effects of the neurokinin NK2 receptor agonist [Lys<sup>5</sup>,MeLeu<sup>9</sup>,Nle<sup>10</sup>]-NKA<sub>(4-10)</sub> on bladder and colorectal activity in minipigsNadia M J Rupniak, Mary A Katofiasc, Lesley Marson, et al.
Journal of Medicinal Chemistry|September 20, 2002
Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraineSandra A Filla, Mark A Winter, Kirk W Johnson, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Life Sciences|July 11, 2002
Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in catsMary A Katofiasc, Jeffrey Nissen, James E Audia, et al.
Journal of Neurotrauma|October 24, 2019
Chronic, Twice-Daily Dosing of an NK2 Receptor Agonist [Lys<sup>5</sup>,MeLeu<sup>9</sup>,Nle<sup>10</sup>]-NKA(4-10), Produces Consistent Drug-Induced Micturition and Defecation in Chronic Spinal RatsLesley Marson, Raymond Keast Piatt, Mary A Katofiasc, et al.
Brain Research|July 26, 2002
The role of 5-HT(1A) receptors in control of lower urinary tract function in catsKarl B Thor, Mary A Katofiasc, Hansjorg Danuser, et al.
Canadian Journal of Physiology and Pharmacology|January 30, 2023
Colorectal and bladder prokinetic activity of [Lys<sup>5</sup>, MeLeu<sup>9</sup>, Nle<sup>10</sup>]-NKA<sub>(4-10)</sub> after intranasal or sublingual delivery in dogsNadia M J Rupniak, Mary A Katofiasc, Jungeun Bae, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 19, 2024
Recent Developments in On-Demand Voiding TherapiesKarl B Thor, Lesley Marson, Mary A Katofiasc, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 20, 2025
Corrigendum to "Recent Developments in On-Demand Voiding Therapies" [The Journal of Pharmacology and Experimental Therapeutics 390 (2024) 302-317]Karl B Thor, Lesley Marson, Mary A Katofiasc, et al.
Neuropeptides|July 21, 2019
Prokinetic effects of the neurokinin NK2 receptor agonist [Lys<sup>5</sup>,MeLeu<sup>9</sup>,Nle<sup>10</sup>]-NKA<sub>(4-10)</sub> on bladder and colorectal activity in minipigsNadia M J Rupniak, Mary A Katofiasc, Lesley Marson, et al.
Journal of Medicinal Chemistry|September 20, 2002
Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraineSandra A Filla, Mark A Winter, Kirk W Johnson, et al.
Pageof 1